Pharma Focus Asia

Cholesgen Enters into Drug Discovery Collaboration and Agreement with AstraZeneca

Saturday, June 17, 2023

Cholesgen has recently announced a three-year collaboration with AstraZeneca to advance research and development in hypercholesterolaemia and related metabolic diseases.

During this collaboration, Cholesgen and AstraZeneca will combine their strengths and expertise to focus on selected targets from Cholesgen's early-stage portfolios. Cholesgen will receive an initial payment and a pre-defined licence package for each qualified drug candidate nominated by AstraZeneca to proceed into clinical development.

This collaboration between Cholesgen and AstraZeneca aims to achieve two primary objectives such as validating genetic drug targets and advancing therapeutic molecules into clinical development. 

By combining their efforts and expertise, the partnership has the potential to expedite the development of groundbreaking medicines that will bring significant benefits to patients suffering from hypercholesterolemia and related metabolic diseases.

A joint research committee oversees the efforts of both Cholesgen and AstraZeneca researchers to ensure effective collaboration and work closely together on target validation and target generation to identify promising drug candidates.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024